[Dry goods] IVD industry chain series of chemiluminescence topics (on)

There is a news that happened in Shanghai: a gentleman did a tumor marker test, a community hospital gave an abnormal result, and a secondary hospital gave a normal result. Later, the community hospital joined a third-level hospital to do the same with the same equipment. Detection. Finally, through other means of examination, such as B-ultrasound, endoscopy and pathology, it is determined that he does not have much cancer risk. This case also involves a third-party inspection agency, the temporary inspection center. It can be seen that there are many corresponding manufacturers for the same test item, but the results between them are not comparable. The significance of the test is more on the evaluation and monitoring of treatment. This involves a traceability issue.

Next review: [dry goods] IVD industry chain series of chemiluminescence topics (below)

Immunization This market segment has many characteristics, and immunoassay also has a lot of room for development because it is cheaper and can assist doctors in the initial screening of patients. The range of diseases involved is wide, and the early diagnosis advocated by the state. Prevention and control, etc. also make a lot of sense. Following the changes in the environment and the prevention and control of national medical reform in the prevention and treatment of chronic diseases, the IVD field has received more and more government resources, and more and more domestic and foreign institutions have made great investments in the IVD field.

Below we will focus on the prospects and challenges of China's luminescent immune market, and how investors should be treated in the process:

In 2013, the global IVD market reached 46.6 billion US dollars, with a compound annual growth rate of nearly 5% in five years and more than 4.6 billion US dollars in China. In the global recession of IVD field, China maintained double-digit growth in both biochemical and immune markets in 2013 and 2014, which also raised the development prospects of global IVD. Foreign companies also see potential and opportunities in China. Everyone is concerned about the potential of listed companies in the fields of immunodiagnosis, molecular diagnosis and POCT. However, companies with a certain scale and relatively stable development in the market must have traditional and conventional businesses such as biochemistry. The mature market immunization share accounts for about 18%, and biochemistry has dropped to 15%. In the past few years, China’s biochemical share has accounted for more than 30%. In recent years, its share has also declined year by year. This is because the overall market capacity is growing at a high rate, reflected in the growth of the immunization share, in addition to the growth in the field of molecular diagnostics and POCT.

A 2010 research report showed that the global diagnostic market for China had begun to predict, and the areas of rapid development include immunodiagnosis, molecular biology and POCT. In that year, the total market value was 3 billion US dollars, and it is predicted to reach 5 billion US dollars in 2017. In fact, the amount of China's IVD market in 2014 has exceeded 5.7 billion US dollars. The potential and rapid development of China's diagnostic market far exceeded expectations. The biggest contributor to this process is the immunodiagnostic market. At the same time, molecular diagnosis and POCT are also growing rapidly in anticipation, but in fact, there is no breakthrough growth, which is mainly due to the guidance of national policies. In the previous year, the state had stopped calling for genetic testing qualifications. In addition, the method of distinguishing the methodology also caused a certain degree of slowdown in the development of POCT. But since the end of last year, these obstacles have been removed. So these markets are still very promising.

Regarding biochemical diagnostic equipment, Mindray, which is domestically focused on this field, has a very large market share. Many foreign companies' installed equipment is already using our local reagents. For industries with relatively low technical barriers such as biochemistry, some companies focus on the development of high-speed, automated instruments and equipment, while others focus on the development and production of reagents. Can immune immunity repeat the trend of biochemistry? Most of the immunodiagnostic equipment is imported, and the data in 2013 shows that domestic equipment only accounts for 6%. The biggest difference between biochemistry and immunity is the openness and closure of the system. The technical barriers to immunization are high and the closure is strong, which restricts the development of domestic manufacturers to a certain extent.

Regarding the composition of foreign-invested companies' IVD business in China, the contribution of immunization is very large. Many foreign-funded enterprises spend a lot of resources on equipment placement and cooperation with third-party leasing companies, in order to seize the rapid development of immunization market share. At present, domestic equipment and reagents account for 34% of the field of immunization, and most of them are monopolized by giants. To measure the development potential of a company, it is necessary to pay attention to its inspection project menu and future investment plans, and learn to conduct objective evaluation.

Regarding the issue of the installed capacity that everyone is paying more attention to in the market, it is estimated that by the end of last year, the new industry will have about 4,000 installed units. Most foreign-funded enterprises and new industries have different areas of development. The new industry has already occupied more than 1,000 tertiary hospitals. The strategy is to gradually penetrate and occupy more secondary hospitals and county-level hospitals. Our domestic enterprises are striving for the nationals in a down-to-earth manner, and their products and channels are in line with the original intention of medical reform to improve the level of primary medical care . Basic hospitals have the need to purchase more medical equipment , so most of the customers are hospitals in Baiqiang County, and some secondary hospitals in medium-sized cities.

Baby Electrical

Baby Electrical,Baby Hair Clipper,Baby Manicure Set,Safety Baby Hair Clipper

NINGBO YOUHE MOTHER&BABY PRODUCTS CO.,LTD , https://www.oembreastpump.com